OrbiMed
VC Fund
New York, United States
OrbiMed is a healthcare-dedicated investment firm, with approximately $5 billion in assets under management. OrbiMed's investment advisory business was founded in 1989 with a vision to invest across the spectrum of healthcare companies: from private start-ups to large multinational companies. OrbiMed manages the Caduceus Private Investmentsseries of venture capital funds and a family of public equity investment funds.
- Total investments:
- 740
- Last investment:
- Lead investor:
- 35%
- Fund size:
- $192M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries OrbiMed invests in
Stages OrbiMed invests in
Countries OrbiMed invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 25 contacts → | |||
Round size
- Series A
- $9.8M–$140M
- Series B
- $24M–$148M
- Series C
- $19M–$160M
Investment Focus
Industry
- Biotechnology 288 (39%)
- Health Care 220 (30%)
- Medical 117 (16%)
- Pharmaceutical 110 (15%)
- Therapeutics 101 (14%)
Stage
- Series B 127 (17%)
- Series A 106 (14%)
- Series C 85 (11%)
- Funding Round 53 (7%)
- Post-IPO Equity 53 (7%)
Country
- United States 238 (32%)
- China 47 (6%)
- Israel 21 (3%)
- Canada 12 (2%)
- United Kingdom 9 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Dina Chaya
Partner
|
Partner | Total investments: 7 | Find email | |
Kevin Koch
Venture Partner
|
Venture Partner | Total investments: 3 | Find email | |
Rishi Gupta
Private Equity Partner
|
Private Equity Partner | Total investments: 12 | Find email | |
Sunny Sharma
Senior Managing Director
|
Senior Managing Director | Total investments: 10 | Find email | |
Tadd S. Wessel
Managing Director
|
Managing Director | Total investments: 10 | Find email | |
| See all 25 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Intellia Therapeutics is a genome editing company that develops curative gene-editing treatments. It can positively transform the lives of people living with severe and life-threatening diseases. IIntellia holds exclusive access to one of the most comprehensive intellectual property platforms available for the therapeutic use of CRISPR-Cas9. Thecompany is advancing a broad pipeline toward clinical development, including ex Vivo, and in vivo approaches. Intellia Therapeutics was formed in 2014 and is headquartered in Cambridge, Massachusetts. | $400M / Post-IPO Debt / Sep 04, 2026 | ||
| Leal Therapeutics develops novel therapeutics for patients. | $30M / Series A / Aug 17, 2026 | ||
| TytoCare is a mobile-health platform and device, allowing anyone to perform self physical examination and remote diagnosis.Tyto Care has three telehealth products: the TytoHome for consumers, TytoPro for professionals, and TytoClinic for remote point-of-care locations. All solutions are designed to replicate a facetious clinician visit andinclude a modular examination tool for examining the heart, lungs, skin, throat, ears, and body temperature; a complete telehealth platform for sharing exam data, conducting live video exams, and scheduling visits; a cloud-based data repository with analytics; and built-in guidance technology and machine learning algorithms to ensure accuracy and ease of use. TytoCare was founded by Dedi Gilad, Ofer Tzadik in 2012 with a vision to put health in the hands of the consumer. | $25M / Venture - Series Unknown / Jul 15, 2026 | ||
| Iswarya Fertility Center provides IVF, IUI, egg donation, azoospermia, ovulation induction, and miscarriage treatment solutions. | $37M / Private Equity / Jul 09, 2026 | ||
| We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics. | $67.4M / Series D / Jul 07, 2026 | ||
| Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras. The company was founded by Carolyn R. Bertozzi in 2019 and is based in San Diego, California, USA. | $75M / Series D / Jun 25, 2026 | ||
| Asian Institute of Medical Sciences is a 425 bedded super specialty hospital in Delhi NCR, India which is dedicated to provide accessible, affordable and best available healthcare services in India. Accredited by NABH and NABL, Asian Hospital Faridabad provides preventive, diagnostic, therapeutic, rehabilitative, palliative and supportive servicesall under one roof and is designed to meet patient care and research requirements of the new millennium.Asian Institute of Medical Sciences offers comprehensive multi-specialty tertiary care facilities through its 14 centres of excellence.- ASIAN CANCER CENTRE - ASIAN CENTRE FOR BONE MARROW TRANSPLANT - ASIAN HEART CENTRE - ASIAN CENTRE FOR ADVANCED SURGERY- ASIAN CENTRE FOR NEUROLOGY AND NEUROSURGERY - ASIAN CENTRE FOR UROLOGY AND KIDNEY TRANSPLANT - ASIAN CENTRE FOR RENAL DISEASES - ASIAN CENTRE FOR BONE AND JOINTS - ASIAN CENTRE FOR ADVANCED IMAGING - ASIAN CENTRE FOR GASTROENTEROLOGY - ASIAN CENTRE FOR MOTHER AND CHILD- ASIAN CENTRE FOR BARIATRIC & METABOLIC SURGERY - ASIAN CENTRE FOR AESTHETIC SURGERY & MEDICINE - ASIAN IVF CENTRE | $44M / Debt Financing / Jun 19, 2026 | ||
| Trunative is a producer and distributor of nutrition products under the TruNativ brand targetting health and fitness enthusiasts. | $30M / Series B / Jun 16, 2026 | ||
| Trunative is a producer and distributor of nutrition products under the TruNativ brand targetting health and fitness enthusiasts. | Secondary Market / Jun 16, 2026 | ||
| Q32 Bio is a biotechnology company developing treatments for patients with severe autoimmune and inflammatory diseases. Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief.Q32 Bio consists of ateam of scientists and industry veterans with strong expertise in immunology. The team has a strong track record of discovering and developing new and innovative therapies. | $55M / Post-IPO Equity / May 26, 2026 | ||
| See all 740 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does OrbiMed invest in?
OrbiMed invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series A stage. Most of the 740 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is OrbiMed's check size?
OrbiMed typically joins rounds of $9.8M–$140M at Series A, $24M–$148M at Series B and $19M–$160M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds OrbiMed participates in.
How do I contact OrbiMed?
Public channels for OrbiMed include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at OrbiMed?
The team at OrbiMed includes Dina Chaya (Partner), Kevin Koch (Venture Partner) and Rishi Gupta (Private Equity Partner), among 25 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
